S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Xenetic Biosciences Stock Forecast, Price & News

-0.05 (-4.42%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
130,687 shs
Average Volume
111,802 shs
Market Capitalization
$14.46 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Xenetic Biosciences logo

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.


15 Best High Volume Stocks to Buy Now
July 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$440 thousand
Cash Flow
$0.76 per share
Book Value
$1.40 per share


Net Income
$-10.89 million
Net Margins
Pretax Margin




Free Float
Market Cap
$14.46 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.18 out of 5 stars

Medical Sector

1218th out of 1,419 stocks

Pharmaceutical Preparations Industry

587th out of 685 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

How has Xenetic Biosciences' stock price been impacted by COVID-19?

Xenetic Biosciences' stock was trading at $0.7031 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBIO stock has increased by 53.6% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 140,000 shares, an increase of 263.6% from the December 15th total of 38,500 shares. Based on an average daily volume of 266,000 shares, the short-interest ratio is currently 0.5 days.
View Xenetic Biosciences' Short Interest

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Xenetic Biosciences

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its earnings results on Thursday, November, 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.20 million. Xenetic Biosciences had a negative net margin of 511.13% and a negative trailing twelve-month return on equity of 37.58%.
View Xenetic Biosciences' earnings history

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu Biopharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $1.08.

How much money does Xenetic Biosciences make?

Xenetic Biosciences has a market capitalization of $14.46 million and generates $440 thousand in revenue each year. The company earns $-10.89 million in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Xenetic Biosciences have?

Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

Where are Xenetic Biosciences' headquarters?

Xenetic Biosciences is headquartered at 40 Speen Street Suite 102, Framingham MA, 01701.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.